• Explore /
  • Poster
  • / A multicenter, single-arm, phase II study of nivolumab in patients with biliary tract cancer with a PD-L1 combined positive score ≥ 1.

A multicenter, single-arm, phase II study of nivolumab in patients with biliary tract cancer with a PD-L1 combined positive score ≥ 1.

Abstract Poster

Authors

null

Masayuki Furukawa

National Kyushu Cancer Center, Fukuoka, Japan;

Masayuki Furukawa , Makoto Ueno , Daisuke Sakai , Kota Ouchi , Yasuo Hamamoto , Hiroshi Aikata , Masato Ozaka , Hidetaka Tsumura , Kunihiro Tsuji , Shoji Kubo , Tomohiro Nishina , Akio Katanuma , Chigusa Morizane , Masafumi Ikeda , Nobumasa Mizuno , Takashi Inagaki , Kazuhiko Shioji , Junji Furuse

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

JapicCTI-205097

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 533)

DOI

10.1200/JCO.2023.41.4_suppl.533

Abstract #

533

Poster Bd #

C3

Abstract Disclosures

Similar Posters

First Author: John Ebben

First Author: Panpan Zhang

First Author: Vaibhav Sahai

Poster

2023 ASCO Gastrointestinal Cancers Symposium

The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation.

The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation.

First Author: Sun Young Jeong